Mitochondrial amplification selectively increases doxorubicin sensitivity in breast cancer cells with acquired antiestrogen resistance.

Abstract

The metabolic phenotype of cancer, characterized by uncoupled mitochondrial respiration and increased mitochondrial oxidative stress, is an attractive pharmacological target for sensitizing cancer cells to therapies that rely on oxidative stress for their tumor specific cytotoxicity. The identification of specific cancer sub-types for which metabolic priming of tumors prior to chemotherapy is beneficial is critical, particularly in heterogeneous diseases such as breast cancer. The effects of the thiazolidinedione drug troglitazone were examined in normal mammary epithelial cells and cancer cell lines representing three clinically relevant breast cancer phenotypes. Endpoints measured were PGC1α mRNA expression, proliferation, cell cycle phase distribution, mitochondrial capacity and superoxide generation, and sensitivity to the chemotherapy drug doxorubicin. Troglitazone increases expression of PGC1α, a key mediator of mitochondrial biogenesis, in normal mammary epithelial cells and in breast cancer cell lines. The induction of PGC1α mRNA is at least partially dependent on PPARγ activation. In estrogen receptor negative cells and cells with acquired antiestrogen resistance, troglitazone treatment increased mitochondrial superoxide production and mitochondrial capacity. At pharmacologically achievable doses, troglitazone pretreatment significantly enhanced the sensitivity of cancer cells to the chemotherapy agent doxorubicin. This effect was most dramatic in estrogen receptor positive cells with acquired antiestrogen resistance, in which troglitazone and doxorubicin combined had superadditive effects compared to treatment with either agent alone. In contrast, troglitazone treatment did not appreciably sensitize non-malignant mammary epithelial cells to doxorubicin induced cytotoxicity, despite increasing PGC1α mRNA. These data suggest that troglitazone or a similarly acting compound could be used to selectively prime tumor cells to the cytotoxic effects of anticancer agents such as doxorubicin and ionizing radiation. This novel treatment strategy may be most effective in women with antiestrogen insensitive tumors, a patient population with historically poor response to traditional therapies.

• Authors: Andrew Skildum, Kenneth Dornfeld, Kendall Wallace
• Journal: Breast cancer research and treatment (Breast Cancer Res Treat) Vol. 129 Issue 3 Pg. 785-97 (Oct 2011) ISSN: 1573-7217 [Electronic] Netherlands
• PMID: 21128112 (Publication Type: Journal Article, Research Support, N.I.H., Extramural)

Chemical References

• Antibiotics, Antineoplastic
• Chromans
• Estrogen Receptor Modulators
• Heat-Shock Proteins
• PPAR gamma
• PPARGC1A protein, human
• Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
• Reactive Oxygen Species
• Receptors, Estrogen
• Thiazolidinediones
• Transcription Factors
• Rosiglitazone
• Doxorubicin
• Troglitazone

Topics

• Antibiotics, Antineoplastic (pharmacology)
• Antineoplastic Combined Chemotherapy Protocols
• Breast Neoplasms (drug therapy, pathology)
• Cell Cycle (drug effects)
• Cell Line, Tumor
• Cells, Cultured
• Chromans (administration & dosage, pharmacology)
• Doxorubicin (administration & dosage, pharmacology)
• Drug Resistance, Neoplasm (drug effects)
• Epithelial Cells (drug effects, metabolism)
• Estrogen Receptor Modulators (pharmacology)
• Female
• Heat-Shock Proteins (genetics, metabolism)
• Humans
• Mitochondria (drug effects, metabolism)
• PPAR gamma (metabolism)
• Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
• Reactive Oxygen Species (metabolism)
• Receptors, Estrogen (metabolism)
• Rosiglitazone
• Thiazolidinediones (administration & dosage, pharmacology)
• Transcription Factors (genetics, metabolism)
• Troglitazone